Pharmacology, Toxicology and Pharmaceutical Science
Acute Heart Failure
100%
Heart Failure
68%
Biological Marker
52%
Creatinine
35%
Disease
27%
Cardiovascular Disease
26%
Chronic Kidney Failure
26%
Non Insulin Dependent Diabetes Mellitus
25%
Placebo
22%
Dapagliflozin
21%
Adverse Drug Reaction
21%
All Cause Mortality
20%
Brain Natriuretic Peptide
19%
Adverse Event
17%
Malignant Neoplasm
17%
Terminal Illness
16%
Rolofylline
15%
Head and Neck Cancer
14%
Primary Tumor
14%
Advanced Cancer
14%
Clinical Trial
13%
Progression Free Survival
11%
Second-Generation Antidepressant
10%
Fluoxetine
10%
Randomized Controlled Trial
10%
Event Free Survival
10%
Prevalence
10%
Adverse Outcome
9%
Recurrent Disease
9%
Growth Differentiation Factor 15
8%
Disulfide
8%
Tolerability
8%
Comorbidity
8%
Metabolic Syndrome X
8%
Galectin 3
8%
Cardiovascular Mortality
7%
Coronary Artery Disease
7%
Hospital Mortality
7%
Atrioventricular Septal Defect
7%
Rheumatoid Arthritis
7%
Paroxetine
7%
Lung Cancer
7%
Alzheimer's Disease
7%
Drug Development
7%
Alanine Aminotransferase
7%
Oral Antidiabetic Agent
7%
Procalcitonin
7%
Sertraline
7%
Dyspnea
7%
Carcinogenicity
7%
Medicine and Dentistry
Heart Failure
49%
Acute Decompensated Heart Failure
40%
Kidney Function
30%
Maturity Onset Diabetes of the Young
28%
Health Care Cost
25%
Chronic Kidney Disease
25%
Biological Marker
24%
Dapagliflozin
21%
Quality of Life
19%
Radiation Therapy
19%
Creatinine
16%
Disease
16%
Cardiovascular Disease
15%
Sex Difference
14%
Blood Pressure
14%
Lung Transplantation
14%
Proton Therapy
14%
Observational Study
14%
Disease Management
14%
Copeptin
14%
Health Technology
13%
Urinary System
13%
Cost-Effectiveness Analysis
12%
Cardiovascular System
11%
Photon Therapy
11%
Hazard Ratio
11%
Clinical Trial
10%
Primary Prevention
10%
Attitude
9%
Technology Assessment
9%
Systolic Blood Pressure
9%
Adverse Outcome
9%
Randomized Controlled Trial
8%
Meta-Analysis
8%
Clinical Decision Making
8%
Medicine
7%
Diagnosis
7%
Coronary Artery Disease
7%
Cumulative Incidence
7%
Diabetes
7%
Atrioventricular Septal Defect
7%
Life Expectancy
7%
Progression Free Survival
7%
Hospital Mortality
7%
Oral Antidiabetic Agent
7%
Impaired Glucose Tolerance
7%
Advanced Cancer
7%
Anticarcinogen
7%
Diuretic Therapy
7%
Nurse
7%
Keyphrases
Acute Heart Failure
62%
Heart Failure
26%
Confidence Interval
19%
Prognostic Value
18%
Patients with Heart Failure
17%
Heart Failure Patients
17%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
16%
Rolofylline
15%
Hazard Ratio
15%
Net Monetary Benefit
14%
Patient Preference Trial
14%
Novel Biomarkers
14%
Blood Pressure
14%
Dapagliflozin
14%
Prospective Observational Study
14%
Galectin-3 (Gal-3)
14%
Type 2 Diabetes Mellitus (T2DM)
14%
All-cause Mortality
13%
Preference Information
12%
Renal Function
12%
Netherlands
12%
Clinical Characteristics
11%
Chronic Kidney Disease
11%
Coaching
10%
Growth Differentiation factor-15 (GDF-15)
10%
Patient Preference
9%
Adverse Outcomes
9%
Predictive Value
9%
Clinical Outcomes
9%
Heart Failure Hospitalization
9%
Plasma Biomarkers
8%
Disulfide
8%
Clinical Trials
8%
Randomized Controlled Trial
8%
Odds Ratio
8%
Competing Risks
8%
Low Risk
8%
Systolic Blood Pressure
7%
Cardiovascular Disease Events
7%
Multi-criteria Model
7%
Software Reuse
7%
Reuse Practices
7%
Long-term Compliance
7%
New Medical Technologies
7%
Probability Elicitation
7%
Acute Decompensated Heart Failure
7%
Real-life Case Studies
7%
Product Planning
7%
Release Planning
7%
Extreme Programming
7%
